On Tuesday, Agios Pharmaceuticals Inc (NASDAQ: AGIO) opened higher 3.34% from the last session, before settling in for the closing price of $33.26. Price fluctuations for AGIO have ranged from $23.42 to $62.58 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -162.17% at the time writing. With a float of $55.39 million, this company’s outstanding shares have now reached $57.89 million.
Let’s look at the performance matrix of the company that is accounted for 488 employees. In terms of profitability, gross margin is 83.22%, operating margin of -1188.86%, and the pretax margin is 1917.72%.
Agios Pharmaceuticals Inc (AGIO) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Agios Pharmaceuticals Inc is 4.37%, while institutional ownership is 105.19%. The most recent insider transaction that took place on Jul 01 ’25, was worth 140,608. Before that another transaction happened on Jun 24 ’25, when Company’s Chief Legal Officer sold 2,799 for $33.54, making the entire transaction worth $93,878. This insider now owns 28,650 shares in total.
Agios Pharmaceuticals Inc (AGIO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -162.17% per share during the next fiscal year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
Check out the current performance indicators for Agios Pharmaceuticals Inc (AGIO). In the past quarter, the stock posted a quick ratio of 17.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 53.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.29, a number that is poised to hit -1.81 in the next quarter and is forecasted to reach -6.64 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Agios Pharmaceuticals Inc (NASDAQ: AGIO) saw its 5-day average volume 0.4 million, a negative change from its year-to-date volume of 0.66 million. As of the previous 9 days, the stock’s Stochastic %D was 33.60%.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 84.43%, which indicates a significant increase from 47.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 36.95% in the past 14 days, which was lower than the 44.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.31, while its 200-day Moving Average is $37.56. Nevertheless, the first resistance level for the watch stands at $35.31 in the near term. At $36.25, the stock is likely to face the second major resistance level. The third major resistance level sits at $37.47. If the price goes on to break the first support level at $33.15, it is likely to go to the next support level at $31.93. The third support level lies at $30.99 if the price breaches the second support level.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
There are currently 57,915K shares outstanding in the company with a market cap of 1.99 billion. Presently, the company’s annual sales total 36,500 K according to its annual income of 673,730 K. Last quarter, the company’s sales amounted to 8,730 K and its income totaled -89,290 K.
